Study to Evaluate the Performance of Navigated TKA With OrthoPilot® pheno4u TKA Level 1
TKA4U
Prospective, Single-arm, Multicenter Study to Evaluate the Performance of Navigated Total Knee Arthroplasty Using the OrthoPilot and the Software pheno4u TKA Level 1
1 other identifier
observational
120
2 countries
4
Brief Summary
The purpose of this PMCF study is to demonstrate the accuracy of navigation using the new pheno4uTKA Level 1 software for OrthoPilot Elite® and to evaluate its safety and performance. Patient-related outcome measures (PROM) will be acquired to investigate functional outcome and patient satisfaction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2025
Typical duration for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 25, 2025
CompletedFirst Posted
Study publicly available on registry
May 2, 2025
CompletedStudy Start
First participant enrolled
October 7, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2028
November 17, 2025
November 1, 2025
1.7 years
April 25, 2025
November 14, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Comparison of the surgical accuracy between the new OrthoPilot Software and the previous OrthoPilot Software
The primary variable delta (aHKA), is defined as the difference in the arithmetic hip-knee-angle (aHKA) between the 3 months postoperative and the intraoperatively planned value. The aHKA is calculated as the difference of the mechanical medial proximal tibial angle (MPTA) and the mechanical lateral distal femoral angle (LDFA), both measured in degrees.
3 months post OP
Secondary Outcomes (8)
Implant survival
ongoing, up to 2 years follow-up
Oxford Knee Score (OKS)
Preoperative,3 months-, 12 months and 2 years post operative
Forgotten Joint Score (FJS)
Preoperative,3 months-, 12 months and 2 years post operative
Quality of Life (EQ-5D-5L)
Preoperative, Postoperative 3 Months + /- 6 weeks, Postoperative 12 months + /- 6 weeks, Postoperative 2 year + /- 3 months
NET Promotor Score (NPS)
Postoperative 3 Months + /- 6 weeks, Postoperative 12 months + /- 6 weeks, Postoperative 2 year + /- 3 months
- +3 more secondary outcomes
Study Arms (1)
pheno4u TKA Level 1
Navigation of TKA (Total Knee Arthroplasty) using the new pheno4uTKA Level 1 software for OrthoPilot Elite®.
Interventions
The OrthoPilot® Software Pheno4u TKA Level 1 is an application software for computer aided navigation of surgical instruments and serves (in combination with compatible hardware and compatible navigated instruments) as an optional aid for the surgeon during the preparation of the implant site for a compatible knee endoprosthesis.
Eligibility Criteria
Patients between 18 and 80 years of age having indication for a fixed-bearing total knee endoprosthesis, without retropatellar arthrosis requiring patella resurfacing
You may qualify if:
- Indication for a TKA with the OrthoPilot® Navigation System with a Aesculap total knee endo-prosthesis
- Written signed informed consent of patient
- Willingness and mental ability to participate at the long-term follow-up examinations
You may not qualify if:
- Pregnancy
- Patients \< 18 years or \> 80 years
- Patients unable to participate at the follow-up examination (physically, mentally)
- Previous joint replacement at the index knee
- ASA classification \> 3 ( ASA I: A healthy patient without systemic diseases. ASA II: A patient with a mild systemic disease that is well controlled (e.g., well-controlled diabetes or hypertension). ASA III: A patient with a severe systemic disease that causes functional limitations (e.g., poorly controlled diabetes, COPD). ASA IV: A patient with a life-threatening systemic disease (e.g., severe heart failure, sepsis). ASA V: A dying patient who is not expected to survive without the operation. ASA VI: A deceased patient whose organs are being removed for donation.)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Aesculap AGlead
- Raylytic GmbHcollaborator
Study Sites (4)
Šumperk Hospital Inc.
Šumperk, 78701, Czechia
Klinikum Konstanz GmbH
Konstanz, Baden-Wurttemberg, 78464, Germany
Park-Klinik Weißensee
Berlin, 13086, Germany
Universitätsklinikum Carl Gustav Carus
Dresden, 01307, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jörg Lützner, Prof. Dr.
Universitätsklinikum Carl Gustav Carus
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 25, 2025
First Posted
May 2, 2025
Study Start
October 7, 2025
Primary Completion (Estimated)
July 1, 2027
Study Completion (Estimated)
June 1, 2028
Last Updated
November 17, 2025
Record last verified: 2025-11